Per the official summary available on congress.gov-HR8454, The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
Finally, the act includes various other provisions, including provisions that
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
A federal regulator cannot terminate or limit the deposit insurance or share insurance of a depository institution […] solely because the depository institution provides or has provided financial services to a cannabis-related legitimate business or service provider…
prohibit, penalize, or otherwise discourage a depository institution from providing financial services to a cannabis-related legitimate business…
recommend, incentivize, or encourage a depository institution not to offer financial services to an account holder, or to downgrade or cancel the financial services offered to an account holder solely because [of their involvement with the cannabis industry]…
take any adverse or corrective supervisory action on a loan made to [a CRB or related person]…
Federal Financial Institutions Examination Council shall develop uniform guidance and examination procedures for depository institutions that provide financial services to cannabis-related legitimate businesses and service providers.
Decriminalization of marijuana as a controlled substance. This includes state authority over transportation of product in each state, regulated in the same manner as though product had been produced in that state.
Three federal regulatory authorities: The Bureau of Alcohol, Tobacco, Firearms, and Explosives; The Department of Health and Human Services; and The Department of Treasury.
Excise taxes starting at 10% during the first year of legalization, then increasing by 5% to 25% by years 4 and 5.
Research and studies on the societal impact of marijuana legalization including the efficacy of medical marijuana as a treatment for certain diseases, community reinvestment programs, and expungements for certain cannabis records.
Establishment of an FDA Center for Cannabis Products to properly regulate all cannabis products including CBD, product standards/safety and recalls; includes the creation of a Cannabis Products Advisory Committee to oversee product regulation.
Medical Marijuana and Cannabidiol Research Expansion Act (HR 8454)
From the bill summary:
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. […]
allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients;